{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:25:30Z","timestamp":1787063130048,"version":"build-2736575974"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100014751","name":"Neuraxpharm","doi-asserted-by":"publisher","award":["Funding of the writing of the manuscript"],"award-info":[{"award-number":["Funding of the writing of the manuscript"]}],"id":[{"id":"10.13039\/501100014751","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40261-026-01576-6","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T18:04:33Z","timestamp":1783361073000},"page":"995-1008","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Desvenlafaxine as a Potential First-Line Treatment for Major Depressive Disorder: A Comprehensive Review and Consensus-Based Clinical Perspective on Efficacy, Safety and Patient Selection Profiles"],"prefix":"10.1007","volume":"46","author":[{"given":"Claudia","family":"Carmassi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"de Diego-Adeli\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vian-Lains","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0889-4100","authenticated-orcid":false,"given":"Ciro","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Schneider-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas Mohan","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"1576_CR1","unstructured":"National Collaborating Centre for Mental Health. National Institute for Health and Clinical Excellence: guidance. Depression: the treatment and management of depression in adults (Updated Edition). Leicester: British Psychological Society; 2010."},{"issue":"10","key":"1576_CR2","doi-asserted-by":"publisher","first-page":"e729","DOI":"10.1016\/s2468-2667(21)00047-5","volume":"6","author":"J Arias-de la Torre","year":"2021","unstructured":"Arias-de la Torre J, Vilagut G, Ronaldson A, Serrano-Blanco A, Mart\u00edn V, Peters M, et al. Prevalence and variability of current depressive disorder in 27 European countries: a population-based study. Lancet Public Health. 2021;6(10):e729\u201338. https:\/\/doi.org\/10.1016\/s2468-2667(21)00047-5.","journal-title":"Lancet Public Health"},{"issue":"10312","key":"1576_CR3","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/s0140-6736(21)02143-7","volume":"398","author":"COVID-19 Mental Disorders Collaborators","year":"2021","unstructured":"COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398(10312):1700\u201312. https:\/\/doi.org\/10.1016\/s0140-6736(21)02143-7.","journal-title":"Lancet"},{"key":"1576_CR4","volume-title":"Depression and other common mental disorders: Global health estimates","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Depression and other common mental disorders: Global health estimates. Geneva: World Health Organization; 2017."},{"issue":"9","key":"1576_CR5","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1080\/14656566.2021.1900826","volume":"22","author":"TR Norman","year":"2021","unstructured":"Norman TR, Olver JS. Desvenlafaxine in the treatment of major depression: an updated overview. Expert Opin Pharmacother. 2021;22(9):1087\u201397. https:\/\/doi.org\/10.1080\/14656566.2021.1900826.","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"1576_CR6","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905\u201317. https:\/\/doi.org\/10.1176\/ajp.2006.163.11.1905.","journal-title":"Am J Psychiatry"},{"issue":"1\u20133","key":"1576_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jad.2009.03.012","volume":"120","author":"J de Diego-Adeli\u00f1o","year":"2010","unstructured":"de Diego-Adeli\u00f1o J, Portella MJ, Puigdemont D, P\u00e9rez-Egea R, Alvarez E, P\u00e9rez V. A short duration of untreated illness (DUI) improves response outcomes in first-depressive episodes. J Affect Disord. 2010;120(1\u20133):221\u20135. https:\/\/doi.org\/10.1016\/j.jad.2009.03.012.","journal-title":"J Affect Disord"},{"issue":"4","key":"1576_CR8","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.eurpsy.2009.07.012","volume":"25","author":"MC Serna","year":"2010","unstructured":"Serna MC, Cruz I, Real J, Gasc\u00f3 E, Galv\u00e1n L. Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database. Eur Psychiatry. 2010;25(4):206\u201313. https:\/\/doi.org\/10.1016\/j.eurpsy.2009.07.012.","journal-title":"Eur Psychiatry"},{"key":"1576_CR9","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jad.2023.10.010","volume":"344","author":"EJ Unni","year":"2024","unstructured":"Unni EJ, Gupta S, Sternbach N. Reasons for non-adherence with antidepressants using the Medication Adherence Reasons Scale in five European countries and United States. J Affect Disord. 2024;344:446\u201350. https:\/\/doi.org\/10.1016\/j.jad.2023.10.010.","journal-title":"J Affect Disord"},{"issue":"5","key":"1576_CR10","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.15r01926","volume":"18","author":"J Habert","year":"2016","unstructured":"Habert J, Katzman MA, Oluboka OJ, McIntyre RS, McIntosh D, MacQueen GM, et al. Functional recovery in major depressive disorder: focus on early optimized treatment. Prim Care Companion CNS Disord. 2016;18(5):PCC.15r01926. https:\/\/doi.org\/10.4088\/PCC.15r01926.","journal-title":"Prim Care Companion CNS Disord"},{"key":"1576_CR11","unstructured":"National Institute for Health and Care Excellence (NICE). Guidelines: depression in adults: treatment and management. London: National Institute for Health and Care Excellence (NICE); 2022."},{"key":"1576_CR12","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.","edition":"5"},{"key":"1576_CR13","unstructured":"World Health Organization. International classification of diseases, eleventh revision (ICD-11). 2019\/2021. https:\/\/icd.who.int\/en. Accessed 20 Oct 2024."},{"issue":"Suppl. E1","key":"1576_CR14","first-page":"4","volume":"69","author":"DJ Nutt","year":"2008","unstructured":"Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry. 2008;69(Suppl. E1):4\u20137.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1576_CR15","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4088\/JCP.12059ah1","volume":"74","author":"J Zajecka","year":"2013","unstructured":"Zajecka J, Kornstein SG, Blier P. Residual symptoms in major depressive disorder: prevalence, effects, and management. J Clin Psychiatry. 2013;74(4):407\u201314. https:\/\/doi.org\/10.4088\/JCP.12059ah1.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"1576_CR16","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3109\/15622975.2013.804195","volume":"14","author":"M Bauer","year":"2013","unstructured":"Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, M\u00f6ller HJ, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14(5):334\u201385. https:\/\/doi.org\/10.3109\/15622975.2013.804195.","journal-title":"World J Biol Psychiatry."},{"key":"1576_CR17","unstructured":"US Department of Veterans Affairs, US Department of Defense. Clinical practice guideline for the management of major depressive disorder. 2022. https:\/\/www.healthquality.va.gov\/guidelines\/MH\/mdd\/VADODMDDCPGFinal508.pdf. Accessed 30 Oct 2024."},{"issue":"9","key":"1576_CR18","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/07067437241245384","volume":"69","author":"RW Lam","year":"2024","unstructured":"Lam RW, Kennedy SH, Adams C, Bahji A, Beaulieu S, Bhat V, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults: R\u00e9seau Canadien pour les traitements de l\u2019humeur et de l\u2019anxi\u00e9t\u00e9 (CANMAT) 2023: mise \u00e0 jour des lignes directrices cliniques pour la prise en charge du trouble d\u00e9pressif majeur chez les adultes. Can J Psychiatry. 2024;69(9):641\u201387. https:\/\/doi.org\/10.1177\/07067437241245384.","journal-title":"Can J Psychiatry"},{"issue":"2","key":"1576_CR19","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1124\/jpet.106.103382","volume":"318","author":"DC Deecher","year":"2006","unstructured":"Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006;318(2):657\u201365. https:\/\/doi.org\/10.1124\/jpet.106.103382.","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"1576_CR20","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1517\/14656566.2014.923403","volume":"15","author":"SG Kornstein","year":"2014","unstructured":"Kornstein SG, McIntyre RS, Thase ME, Boucher M. Desvenlafaxine for the treatment of major depressive disorder. Expert Opin Pharmacother. 2014;15(10):1449\u201363. https:\/\/doi.org\/10.1517\/14656566.2014.923403.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"1576_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1017\/s1092852900020204","volume":"14","author":"AH Clayton","year":"2009","unstructured":"Clayton AH, Kornstein SG, Rosas G, Guico-Pabia C, Tourian KA. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr. 2009;14(4):183\u201395. https:\/\/doi.org\/10.1017\/s1092852900020204.","journal-title":"CNS Spectr"},{"issue":"3","key":"1576_CR22","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.09r00845blu","volume":"12","author":"MR Liebowitz","year":"2010","unstructured":"Liebowitz MR, Tourian KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg\/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3):PCC.09r00845. https:\/\/doi.org\/10.4088\/PCC.09r00845blu.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"3","key":"1576_CR23","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/yic.0000000000000121","volume":"31","author":"JL Carrasco","year":"2016","unstructured":"Carrasco JL, Kornstein SG, McIntyre RS, Fayyad R, Prieto R, Salas M, et al. An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2016;31(3):134\u201346. https:\/\/doi.org\/10.1097\/yic.0000000000000121.","journal-title":"Int Clin Psychopharmacol"},{"issue":"6","key":"1576_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1055\/s-0035-1555879","volume":"48","author":"ZG Laoutidis","year":"2015","unstructured":"Laoutidis ZG, Kioulos KT. Desvenlafaxine for the acute treatment of depression: a systematic review and meta-analysis. Pharmacopsychiatry. 2015;48(6):187\u201399. https:\/\/doi.org\/10.1055\/s-0035-1555879.","journal-title":"Pharmacopsychiatry"},{"issue":"12","key":"1576_CR25","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1586\/14737175.8.12.1787","volume":"8","author":"J Kamath","year":"2008","unstructured":"Kamath J, Handratta V. Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008;8(12):1787\u201397. https:\/\/doi.org\/10.1586\/14737175.8.12.1787.","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"1576_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1017\/s1461145705006413","volume":"10","author":"G Debonnel","year":"2007","unstructured":"Debonnel G, Saint-Andr\u00e9 E, H\u00e9bert C, de Montigny C, Lavoie N, Blier P. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol. 2007;10(1):51\u201361. https:\/\/doi.org\/10.1017\/s1461145705006413.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"1576_CR27","doi-asserted-by":"publisher","first-page":"022","DOI":"10.4172\/jbb.1000130","volume":"5","author":"A Nichols","year":"2013","unstructured":"Nichols A, Behrle J, Parks V, Richards L, McGrory S, Posener J, et al. Pharmacokinetics, pharmacodynamics, and safety of desvenlafaxine, a serotonin-norepinephrine reuptake inhibitor. J Bioequiv Bioavailab. 2013;5(1):022\u201330. https:\/\/doi.org\/10.4172\/jbb.1000130.","journal-title":"J Bioequiv Bioavailab"},{"issue":"2","key":"1576_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.64719\/pb.4308","volume":"42","author":"A Oganesian","year":"2009","unstructured":"Oganesian A, Shilling AD, Young-Sciame R, Tran J, Watanyar A, Azam F, et al. Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities. Psychopharmacol Bull. 2009;42(2):47\u201363.","journal-title":"Psychopharmacol Bull"},{"issue":"1","key":"1576_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/JCP.0b013e318192e4c1","volume":"29","author":"S Preskorn","year":"2009","unstructured":"Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, et al. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol. 2009;29(1):39\u201343. https:\/\/doi.org\/10.1097\/JCP.0b013e318192e4c1.","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"1576_CR30","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.4088\/JCP.08m04773blu","volume":"71","author":"KW Lobello","year":"2010","unstructured":"Lobello KW, Preskorn SH, Guico-Pabia CJ, Jiang Q, Paul J, Nichols AI, et al. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J Clin Psychiatry. 2010;71(11):1482\u20137. https:\/\/doi.org\/10.4088\/JCP.08m04773blu.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1576_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2165\/11586630-000000000-00000","volume":"31","author":"AI Nichols","year":"2011","unstructured":"Nichols AI, Focht K, Jiang Q, Preskorn SH, Kane CP. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study. Clin Drug Investig. 2011;31(3):155\u201367. https:\/\/doi.org\/10.2165\/11586630-000000000-00000.","journal-title":"Clin Drug Investig"},{"issue":"5","key":"1576_CR32","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/cpt.3162","volume":"115","author":"X Men","year":"2024","unstructured":"Men X, Taylor ZL, Marshe VS, Blumberger DM, Karp JF, Kennedy JL, et al. CYP2D6 phenotype influences pharmacokinetic parameters of venlafaxine: results from a population pharmacokinetic model in older adults with depression. Clin Pharmacol Ther. 2024;115(5):1065\u201374. https:\/\/doi.org\/10.1002\/cpt.3162.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1576_CR33","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/jcp.0000000000000775","volume":"37","author":"MA Katzman","year":"2017","unstructured":"Katzman MA, Nierenberg AA, Wajsbrot DB, Meier E, Prieto R, Pappadopulos E, et al. Speed of improvement in symptoms of depression with desvenlafaxine 50 mg and 100 mg compared with placebo in patients with major depressive disorder. J Clin Psychopharmacol. 2017;37(5):555\u201361. https:\/\/doi.org\/10.1097\/jcp.0000000000000775.","journal-title":"J Clin Psychopharmacol"},{"key":"1576_CR34","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2147\/ndt.S157708","volume":"14","author":"Y Low","year":"2018","unstructured":"Low Y, Setia S, Lima G. Drug-drug interactions involving antidepressants: focus on desvenlafaxine. Neuropsychiatr Dis Treat. 2018;14:567\u201380. https:\/\/doi.org\/10.2147\/ndt.S157708.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1576_CR35","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4172\/jbb.1000140","volume":"5","author":"A Nichols","year":"2013","unstructured":"Nichols A, Richards LS, Behrle JA, Posener JA, Fruncillo R, Bbbbb A. Effects of age and sex on the pharmacokinetics, safety, and tolerability of oral desvenlafaxine in healthy adults. J Bioequiv Bioavailab. 2013;5:88\u201394. https:\/\/doi.org\/10.4172\/jbb.1000140.","journal-title":"J Bioequiv Bioavailab."},{"issue":"1","key":"1576_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5414\/cpp49003","volume":"49","author":"AI Nichols","year":"2011","unstructured":"Nichols AI, Richards LS, Behrle JA, Posener JA, McGrory SB, Paul J. The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment. Int J Clin Pharmacol Ther. 2011;49(1):3\u201313. https:\/\/doi.org\/10.5414\/cpp49003.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1576_CR37","unstructured":"US Food and Drug Administration. Pristiq. 2008. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/021992s051lbl.pdf. Accessed 17 Aug 2024."},{"issue":"3","key":"1576_CR38","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1017\/s1092852912000648","volume":"17","author":"KA Coleman","year":"2012","unstructured":"Coleman KA, Xavier VY, Palmer TL, Meaney JV, Radalj LM, Canny LM. An indirect comparison of the efficacy and safety of desvenlafaxine and venlafaxine using placebo as the common comparator. CNS Spectr. 2012;17(3):131\u201341. https:\/\/doi.org\/10.1017\/s1092852912000648.","journal-title":"CNS Spectr"},{"key":"1576_CR39","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jad.2023.02.067","volume":"329","author":"Q Zhao","year":"2023","unstructured":"Zhao Q, Fu B, Lyu N, Xu X, Huang G, Tan Y, et al. A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major depressive disorder. J Affect Disord. 2023;329:72\u201380. https:\/\/doi.org\/10.1016\/j.jad.2023.02.067.","journal-title":"J Affect Disord"},{"issue":"9","key":"1576_CR40","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1177\/0269881117719261","volume":"31","author":"RW Lam","year":"2017","unstructured":"Lam RW, Wajsbrot DB, Meier E, Pappadopulos E, Mackell JA, Boucher M. Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: a pooled analysis. J Psychopharmacol. 2017;31(9):1204\u201314. https:\/\/doi.org\/10.1177\/0269881117719261.","journal-title":"J Psychopharmacol"},{"issue":"6","key":"1576_CR41","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/YIC.0000000000000192","volume":"32","author":"D Sarfati","year":"2017","unstructured":"Sarfati D, Evans VC, Tam EM, Woo C, Iverson GL, Yatham LN, et al. The impact of fatigue and energy on work functioning and impairment in patients with major depressive disorder treated with desvenlafaxine. Int Clin Psychopharmacol. 2017;32(6):343\u20139. https:\/\/doi.org\/10.1097\/YIC.0000000000000192.","journal-title":"Int Clin Psychopharmacol"},{"key":"1576_CR42","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.psychres.2018.12.062","volume":"272","author":"E Alonso-Prieto","year":"2019","unstructured":"Alonso-Prieto E, Rubino C, Lucey M, Evans VC, Tam EM, Woo C, et al. Relationship between work functioning and self-reported cognitive complaints in patients with major depressive disorder treated with desvenlafaxine. Psychiatry Res. 2019;272:144\u20138. https:\/\/doi.org\/10.1016\/j.psychres.2018.12.062.","journal-title":"Psychiatry Res"},{"issue":"6","key":"1576_CR43","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1177\/0269881116631649","volume":"30","author":"S Reddy","year":"2016","unstructured":"Reddy S, Fayyad R, Edgar CJ, Guico-Pabia CJ, Wesnes K. The effect of desvenlafaxine on cognitive functioning in employed outpatients with major depressive disorder: a substudy of a randomized, double-blind, placebo-controlled trial. J Psychopharmacol. 2016;30(6):559\u201367. https:\/\/doi.org\/10.1177\/0269881116631649.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"1576_CR44","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12991-025-00552-2","volume":"24","author":"M Vicent-Gil","year":"2025","unstructured":"Vicent-Gil M, Trujols J, Sagu\u00e9s T, Serra-Blasco M, Navarra-Ventura G, Mantellini CL, et al. Insights on the cognitive enhancement effect of desvenlafaxine in major depressive disorder. Ann Gen Psychiatry. 2025;24(1):16. https:\/\/doi.org\/10.1186\/s12991-025-00552-2.","journal-title":"Ann Gen Psychiatry"},{"issue":"10","key":"1576_CR45","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.4088\/JCP.09m05133blu","volume":"70","author":"CN Soares","year":"2009","unstructured":"Soares CN, Kornstein SG, Thase ME, Jiang Q, Guico-Pabia CJ. Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials. J Clin Psychiatry. 2009;70(10):1365\u201371. https:\/\/doi.org\/10.4088\/JCP.09m05133blu.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"1576_CR46","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/YIC.0000000000000031","volume":"29","author":"RW Lam","year":"2014","unstructured":"Lam RW, Endicott J, Hsu MA, Fayyad R, Guico-Pabia C, Boucher M. Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine. Int Clin Psychopharmacol. 2014;29(5):239\u201351. https:\/\/doi.org\/10.1097\/YIC.0000000000000031.","journal-title":"Int Clin Psychopharmacol"},{"key":"1576_CR47","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jad.2016.05.074","volume":"203","author":"RW Lam","year":"2016","unstructured":"Lam RW, Iverson GL, Evans VC, Yatham LN, Stewart K, Tam EM, et al. The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder. J Affect Disord. 2016;203:55\u201361. https:\/\/doi.org\/10.1016\/j.jad.2016.05.074.","journal-title":"J Affect Disord"},{"key":"1576_CR48","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jad.2014.05.011","volume":"166","author":"J Endicott","year":"2014","unstructured":"Endicott J, Lam RW, Hsu MA, Fayyad R, Boucher M, Guico-Pabia CJ. Improvements in quality of life with desvenlafaxine 50mg\/d vs placebo in employed adults with major depressive disorder. J Affect Disord. 2014;166:307\u201314. https:\/\/doi.org\/10.1016\/j.jad.2014.05.011.","journal-title":"J Affect Disord"},{"issue":"3","key":"1576_CR49","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1185\/03007995.2015.1136603","volume":"32","author":"RS McIntyre","year":"2016","unstructured":"McIntyre RS, Fayyad R, Mackell JA, Boucher M. Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg\/d in major depressive disorder. Curr Med Res Opin. 2016;32(3):587\u201399. https:\/\/doi.org\/10.1185\/03007995.2015.1136603.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"1576_CR50","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1089\/jwh.2014.4900","volume":"24","author":"SG Kornstein","year":"2015","unstructured":"Kornstein SG, Clayton AH, Bao W, Guico-Pabia CJ. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women. J Womens Health (Larchmt). 2015;24(4):281\u201390. https:\/\/doi.org\/10.1089\/jwh.2014.4900.","journal-title":"J Womens Health (Larchmt)"},{"issue":"5","key":"1576_CR51","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3390\/jcm8050719","volume":"8","author":"AL Montejo","year":"2019","unstructured":"Montejo AL, Becker J, Bueno G, Fern\u00e1ndez-Ovejero R, Gallego MT, Gonz\u00e1lez N, et al. Frequency of sexual dysfunction in patients treated with desvenlafaxine: a prospective naturalistic study. J Clin Med. 2019;8(5):719. https:\/\/doi.org\/10.3390\/jcm8050719.","journal-title":"J Clin Med"},{"issue":"1","key":"1576_CR52","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.08m00746blu","volume":"12","author":"KA Tourian","year":"2010","unstructured":"Tourian KA, Leurent C, Graepel J, Ninan PT. Desvenlafaxine and weight change in major depressive disorder. Prim Care Companion J Clin Psychiatry. 2010;12(1):PCC.08m00746. https:\/\/doi.org\/10.4088\/PCC.08m00746blu.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"3","key":"1576_CR53","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1017\/s1092852900020125","volume":"14","author":"ME Thase","year":"2009","unstructured":"Thase ME, Kornstein SG, Germain JM, Jiang Q, Guico-Pabia C, Ninan PT. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr. 2009;14(3):144\u201354. https:\/\/doi.org\/10.1017\/s1092852900020125.","journal-title":"CNS Spectr"},{"key":"1576_CR54","doi-asserted-by":"publisher","first-page":"S1035","DOI":"10.1192\/j.eurpsy.2025.2095","volume":"68","author":"K Anurag","year":"2025","unstructured":"Anurag K, Mohapatra H, Dash L. Desvenlafaxine: a causative agent of extrapyramidal side effects [abstract EPV1605]. Eur Psychiatry. 2025;68:S1035.","journal-title":"Eur Psychiatry"},{"issue":"6","key":"1576_CR55","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.clinthera.2013.03.013","volume":"35","author":"S Baird-Bellaire","year":"2013","unstructured":"Baird-Bellaire S, Behrle JA, Parker VD, Patat A, Paul J, Nichols AI. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine. Clin Ther. 2013;35(6):782\u201394. https:\/\/doi.org\/10.1016\/j.clinthera.2013.03.013.","journal-title":"Clin Ther"},{"issue":"10","key":"1576_CR56","doi-asserted-by":"publisher","first-page":"830","DOI":"10.5414\/cp201958","volume":"52","author":"AI Nichols","year":"2014","unstructured":"Nichols AI, Lubaczewski S, Liang Y, Matschke K, Braley G, Ramey T. Open-label, 2-period sequential drug interaction study to evaluate the effect of a 100-mg dose of desvenlafaxine on the pharmacokinetics of tamoxifen when coadministered in healthy postmenopausal female subjects. Int J Clin Pharmacol Ther. 2014;52(10):830\u201341. https:\/\/doi.org\/10.5414\/cp201958.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5","key":"1576_CR57","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/yic.0000000000000223","volume":"33","author":"C El Hage","year":"2018","unstructured":"El Hage C, Ghabrash MF, Dubreucq S, Brissette S, Lesp\u00e9rance F, Lesp\u00e9rance P, et al. A pilot, open-label, 8-week study evaluating desvenlafaxine for treatment of major depression in methadone-maintained individuals with opioid use disorder. Int Clin Psychopharmacol. 2018;33(5):268\u201373. https:\/\/doi.org\/10.1097\/yic.0000000000000223.","journal-title":"Int Clin Psychopharmacol"},{"issue":"12","key":"1576_CR58","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s40261-021-01086-7","volume":"41","author":"N Cardoner","year":"2021","unstructured":"Cardoner N, Sicras-Mainar A, Rejas J, Armada B. Adherence to desvenlafaxine versus usual care and its impact on health outcomes: a comparative real-world clinical study. Clin Drug Investig. 2021;41(12):1055\u201366. https:\/\/doi.org\/10.1007\/s40261-021-01086-7.","journal-title":"Clin Drug Investig"},{"issue":"7","key":"1576_CR59","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/s2215-0366(24)00133-0","volume":"11","author":"J Henssler","year":"2024","unstructured":"Henssler J, Schmidt Y, Schmidt U, Schwarzer G, Bschor T, Baethge C. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. Lancet Psychiatry. 2024;11(7):526\u201335. https:\/\/doi.org\/10.1016\/s2215-0366(24)00133-0.","journal-title":"Lancet Psychiatry"},{"key":"1576_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/jech-2020-214611","author":"MP Hengartner","year":"2021","unstructured":"Hengartner MP, Amendola S, Kaminski JA, Kindler S, Bschor T, Ploderl M. Suicide risk with selective serotonin reuptake inhibitors and other new-generation antidepressants in adults: a systematic review and meta-analysis of observational studies. J Epidemiol Community Health. 2021. https:\/\/doi.org\/10.1136\/jech-2020-214611.","journal-title":"J Epidemiol Community Health"},{"issue":"9","key":"1576_CR61","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1093\/ijnp\/pyy048","volume":"21","author":"S Stubner","year":"2018","unstructured":"Stubner S, Grohmann R, Greil W, Zhang X, Muller-Oerlinghausen B, Bleich S, et al. Suicidal ideation and suicidal behavior as rare adverse events of antidepressant medication: current report from the AMSP Multicenter Drug Safety Surveillance Project. Int J Neuropsychopharmacol. 2018;21(9):814\u201321. https:\/\/doi.org\/10.1093\/ijnp\/pyy048.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1576_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.880496","volume":"13","author":"K Li","year":"2022","unstructured":"Li K, Zhou G, Xiao Y, Gu J, Chen Q, Xie S, et al. Risk of suicidal behaviors and antidepressant exposure among children and adolescents: a meta-analysis of observational studies. Front Psychiatry. 2022;13:880496. https:\/\/doi.org\/10.3389\/fpsyt.2022.880496.","journal-title":"Front Psychiatry."},{"issue":"4","key":"1576_CR63","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/JCP.0b013e3181e6d686","volume":"30","author":"KA Tourian","year":"2010","unstructured":"Tourian KA, Padmanabhan K, Groark J, Ninan PT. Retrospective analysis of suicidality in patients treated with the antidepressant desvenlafaxine. J Clin Psychopharmacol. 2010;30(4):411\u20136. https:\/\/doi.org\/10.1097\/JCP.0b013e3181e6d686.","journal-title":"J Clin Psychopharmacol"},{"key":"1576_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1442490","volume":"15","author":"AR Eugene","year":"2024","unstructured":"Eugene AR. Country-specific psychopharmacological risk of reporting suicidality comparing 38 antidepressants and lithium from the FDA adverse event reporting system, 2017\u20132023. Front Psychiatry. 2024;15:1442490. https:\/\/doi.org\/10.3389\/fpsyt.2024.1442490.","journal-title":"Front Psychiatry"},{"issue":"5","key":"1576_CR65","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/hup.2427","volume":"29","author":"SG Kornstein","year":"2014","unstructured":"Kornstein SG, Guico-Pabia CJ, Fayyad RS. The effect of desvenlafaxine 50 mg\/day on a subpopulation of anxious\/depressed patients: a pooled analysis of seven randomized, placebo-controlled studies. Hum Psychopharmacol Clin Exp. 2014;29(5):492\u2013501. https:\/\/doi.org\/10.1002\/hup.2427.","journal-title":"Hum Psychopharmacol Clin Exp"},{"issue":"3","key":"1576_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12030516","volume":"12","author":"C Prodan-B\u0103rbulescu","year":"2024","unstructured":"Prodan-B\u0103rbulescu C, \u015eecl\u0103man EP, En\u0103tescu V, Faur IF, Ghenciu LA, Tu\u0163ac P, et al. Evaluating the connection between microRNAs and long non-coding RNAs for the establishment of the major depressive disorder diagnosis. Biomedicines. 2024;12(3):516. https:\/\/doi.org\/10.3390\/biomedicines12030516.","journal-title":"Biomedicines"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01576-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01576-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01576-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:32:47Z","timestamp":1787059967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01576-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":66,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1576"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01576-6","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Claudia Carmassi has been a continuing medical education speaker and\/or a consultant or advisor to and\/or has received honoraria from Angelini, Lundbeck, Gedeon Richter, Neuraxpharm, Teva Italia and Viatris. Christoph Correll has been a consultant and\/or advisor to or has received honoraria from AbbVie, Alkermes, Allergan, Angelini, Aristo, Autobahn, Boehringer Ingelheim, Bristol Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Draig, Eli Lilly, Eumentis Therapeutics, Gedeon Richter, GH, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen\/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, MedLink Global, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora Therapeutics, Neuraxpharm, Neurocrine, Neurelis, Neurosterix, NeuShen, Newron, Noven, Novo Nordisk, Orion Pharma, Otsuka, PPD Biotech, Recognify Life Science, Recordati, Relmada, Response Pharmaeutical, Reviva, Rovi, Saladax, Sanofi, Seqirus, Servier, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Terran, Tolmar, Vertex, Viatris and Xenon Pharmaceuticals. He provided expert testimony for Janssen, Lundbeck, Neurocrine and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, IntraCellular Therapies, Relmada, Reviva and Rovi. He has received grant support from Boehringer Ingelheim, Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, MedLink Global, Mindpax, Quantic and Terran. Javier de Diego-Adeli\u00f1o has received grants from the Spanish Ministry of Health Instituto de Salud Carlos III (PI23\/00469) and from the Fundaci\u00f3 La Marat\u00f3 de TV3 (202207-31) and has served as an advisor or continuing medical education speaker for Neuraxpharm, Johnson & Johnson, Lundbeck, Pfizer, Esteve, Viatris and Amgen. Antonio Vian-Lains has served as an advisor or continuing medical education speaker for Neuraxpharm, Johnson & Johnson and Lundbeck. Ciro Oliveira has received honoraria from Angelini Pharma Portugal, AstraZeneca, Bial, GlaxoSmithKline, Jaba Recordati, Johnson & Johnson, Lundbeck, Neuraxpharm and Rovi SA. Vikas Mohan Sharma and Alex Schneider-P\u00e9rez are full-time employees of Neuraxpharm.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors equally contributed to the development of this manuscript by reviewing the relevant literature in preparation for the advisory board meeting, participated in discussions during the meeting and contributed to the interpretation of evidence. All authors reviewed, provided critical comments on and approved the drafts of the manuscript, approved the final version for publication and agree to be accountable for the work.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}